Susquehanna Portfolio Strategies LLC Sells 17,489 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Susquehanna Portfolio Strategies LLC decreased its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 19.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,468 shares of the company’s stock after selling 17,489 shares during the quarter. Susquehanna Portfolio Strategies LLC owned 0.14% of ALX Oncology worth $443,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co bought a new stake in shares of ALX Oncology during the 1st quarter worth approximately $27,000. EntryPoint Capital LLC bought a new stake in ALX Oncology during the first quarter worth $32,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of ALX Oncology by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock valued at $107,000 after purchasing an additional 3,825 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of ALX Oncology in the 2nd quarter valued at $63,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Stock Up 5.3 %

Shares of NASDAQ ALXO opened at $1.97 on Friday. The company has a 50 day simple moving average of $2.91 and a 200 day simple moving average of $8.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.39 and a quick ratio of 4.39. ALX Oncology Holdings Inc. has a 1 year low of $1.76 and a 1 year high of $17.83. The firm has a market cap of $102.64 million, a PE ratio of -0.53 and a beta of 1.01.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.01. On average, research analysts forecast that ALX Oncology Holdings Inc. will post -3.04 EPS for the current year.

Insider Buying and Selling

In other news, insider Jaume Pons sold 20,000 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $7.90, for a total value of $158,000.00. Following the completion of the sale, the insider now owns 593,447 shares of the company’s stock, valued at $4,688,231.30. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 28,398 shares of company stock valued at $200,043 in the last three months. Insiders own 33.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Lifesci Capital downgraded shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Monday, August 12th. UBS Group dropped their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $3.00 target price (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and a consensus price target of $14.00.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.